HCA Healthcare, Inc.

The volume pressure from declining exchange plans is considered temporary and manageable. An unplanned $200 million Medicaid supplemental payment boost across Texas, Georgia, and Tennessee partially offsets exchange-related headwinds, with firms like RBC and Cantor Fitzgerald maintaining high price targets and Overweight ratings.

HCA revised its FY26 guidance downward, now expecting an unfavorable exchange impact of $1.0–$1.2 billion, up from the prior $600–$900 million estimate. Barclays downgraded HCA citing insufficient clarity on exchange volumes and the risk that departing exchange patients shift toward becoming uninsured rather than covered.

Q2 2026 preliminary revenue of $20.23 billion significantly surpassed analyst estimates of $19.385 billion, representing strong year-over-year growth from $18.605 billion. CEO Sam Hazen expressed confidence in navigating the dynamic environment and executing the strategic plan to digitize and grow healthcare networks.

HCA lowered its full-year 2026 revenue guidance to $77.0–$79.5 billion and cut its EPS outlook to $28.70–$30.50 per diluted share. Multiple analysts, including Jefferies and TD Cowen, responded by slashing their price targets, reflecting diminished confidence in earnings predictability amid ongoing payer mix headwinds.

The analyst consensus price target stands at approximately $502.77, implying roughly 23.6% upside from recent trading levels. Jefferies maintained a Buy rating with a $450 target, and the average target across 25 analysts sits at $470.55, suggesting the market has overreacted to near-term headwinds.

HCA's Financhill Stock Score has fallen to 33/100, placing it in the 30–40th percentile of its historical score range and signaling elevated risk. The stock is trading below its 5, 20, and 50-day exponential moving averages, reflecting a strongly negative short-term technical trend and growing downside momentum.